
Releases
Photocure reports Q2 revenue growth as bladder cancer diagnostics expand
Photocure ASA posted second-quarter 2026 revenues of NOK 140 million for its Hexvix/Cysview products, marking a steady increase from the NOK 135.6 million reported during the same period last year. The Oslo-based company is now raising its full-year revenue growth guidance to a range of 8% to 11%.

























